



Ed Boyden is a professor of Biological Engineering and Brain and Cognitive Sciences at the MIT Media Lab and the MIT McGovern Institute.


[FEATURED STORIES](#)

[INDIVIDUAL PROFILE](#)

[SYNTHETIC BIOLOGY NEWS](#)

## From brain prostheses to the 3D brain: Ed Boyden on the future of neuroscience



John Murray  November 19, 2018

Recently I had a chance to chat with MIT neuroscience *wunderkind* Ed Boyden. Boyden, along with Bryan Johnson of [OS Fund](#) and Jane Metcalfe of [NEO.LIFE](#), participated in the keynote fireside chat [Neuroscience + synthetic biology: The neobiological revolution at SynBioBeta 2018](#) last month.

Anywhere Boyden goes, he is undoubtedly the smartest person in the room. The 39-year-old Texas native graduated from MIT at age 19 with three degrees – a bachelor's and master's in electrical engineering and computer science, plus a bachelor's in physics – before moving to Stanford University where he earned a PhD in neuroscience.



Though Boyden has advised a few startups, including [Kernel](#), his abiding interest in neuroscience is not commercial. "I'm not a business person," he tells me. In fact, his interest goes beyond scientific discovery. He wants to better understand the human condition and alleviate the suffering caused by neurological disorders.

## Seeking modern answers to ancient questions

Boyden recalls attending the World Economic Forum in Davos, Switzerland, in 2013, and hearing former Israeli President Shimon Peres lament how humanity has so far failed to bring peace to the world. At one point, Peres looked up and said, "I think it has to be the brain. That's the thing we don't understand yet."

This struck a chord with Boyden. "Over the years," he says, "it really resonated with my ideas about how the brain generates the mind – how it leads to joy and creativity, but also to irrationality and ugliness of human behavior."

Boyden hopes that new technologies for recording and controlling neural activity will someday lead to prosthetics that can restore lost senses, control pathological neural dynamics, and augment cognition and empathy.

But to many, the prospect of prosthetics that cure brain disorders seems out of reach. As a skeptic once put it, if our brains were simple enough to be understood, we would probably not be smart enough to do it. Indeed, the challenge is overwhelming: Our brains contain about 100 billion neurons, with trillions of connections, coordinated with millisecond precision, all packed together so densely that they cannot be adequately studied with an optical microscope.


But Boyden has [never shied away from solving big problems](#). "My long-term goal is to understand the brain with enough precision that we can simulate the computations that occur during decision-making or emotion," he says. "Maybe we could even define what a thought is, computationally." To achieve this, Boyden believes, we must do three things: watch the brain's electrical activity and chemical signaling in action, map the wiring of its neural circuits, and perturb it with an unprecedented level of detail.



Ed Boyden shows Canadian Prime Minister Justin Trudeau his expansion microscopy technology.  
Photo credit: Leanne Wang.


## Science fiction, or the future of neuroscience?

If Boyden's ideas sound like science fiction, consider what he and his colleagues have achieved so far. Boyden gained widespread recognition while in grad school, when he and his collaborator Karl Deisseroth invented the field of optogenetics. By genetically expressing light-sensitive ion channels and pumps in neurons, they created a light switch that precisely controls when those neurons fire or remain quiet. Optogenetics is now widely used by neuroscientists as a research tool and is thought by some to have therapeutic applications as well.



*Optogenetics: molecules enabling neural control by light*

Then, in 2015, Boyden achieved another breakthrough when he, along with graduate students Fei Chen and Paul Tillberg, invented the field of expansion microscopy. The laws of physics limit the resolution of optical microscopes. Therefore, when studying the tiny structures that are important to biological function, researchers previously had to rely on electron microscopes or super-resolution microscopes, which are highly specialized and expensive.



*Expansion microscopy: physical magnification with nanoscale precision.*

Expansion microscopy, on the other hand, is inexpensive and easy to use. It was inspired by the work of MIT physicist Toyochi Tanaka, who in the 1970s discovered a family of “smart” gels that undergo remarkable phase transitions in specific environmental conditions. These gels are now widely used in industrial applications, but they are probably best known for being the magic ingredient in disposable diapers.

optical microscope. As an added bonus, they could stain specific molecules in the sample to identify their density and distribution in relation to the biological structures of interest.

Because expansion microscopy can generate extensive, detailed data sets from biological samples, researchers now use it for [machine learning to diagnose diseases](#). For instance, Boyden and his colleagues have used it to distinguish early-stage breast lesions with high or low risk of progressing to cancer, a task that is challenging for humans.

“Cancer biopsies are just the beginning,” he says. “We have a new pipeline for taking clinical samples and expanding them, and we are finding that we can apply expansion to many different diseases. Expansion will enable computational pathology to take advantage of more information in a specimen than previously possible.”

## The basis for a computer model of the brain

In his neuroscience research, Boyden aims to combine expansion microscopy with voltage-signaling molecules to create a 3D image of the brain, and use optogenetics to perturb its neural circuits. This, he believes, could lead to a theoretical understanding that is sufficiently detailed to serve as the basis for a computer model of the brain.



brain stimulation has successfully treated many patients suffering from Parkinson's disease, obsessive compulsive disorder, epilepsy, or depression, it requires implanting electrodes in the brain.

Temporal interference uses electrodes on the outside of the patient's head that transmit high-frequency electrical fields into the brain. These electrical fields oscillate too quickly for neurons to respond to them. But they interfere with one another in such a way that, where they intersect, they produce a small region of low-frequency current that can stimulate neurons locally without affecting the surrounding tissue. Unlike other noninvasive techniques for brain stimulation, temporal interference can reach deep inside the brain, yet it does so without disrupting neurons close to the surface.

Temporal interference has only been tested in mice so far, but it can potentially offer insights into how the human brain works and perhaps treat neurological disorders as well.

Boyden is certainly a wellspring of innovative ideas — but more than this, he is a scientific pioneer. Not content to let the human mind remain forever mysterious, he is building a toolkit to explore it with scientific rigor. When his work is done, our understanding of the world and ourselves will never be the same.



## John Murray

John Murray is a private investor and freelance writer based in Princeton, NJ..He is formerly CEO of Current Capital Management LLC and Senior Hedge Fund Manager for Goldman Sachs Asset Management. He holds an M.S. in High-Energy Physics from the University of Michigan.

[VIEW ALL POSTS](#)



SIGN UP

## You may also like

Digest #253 – \$1.2 billion in 1 week: Moderna \$604M IPO, Zymergen \$400M, Synthorx \$131M IPO, Synthace \$25.6M, Elemental Machines \$9M, GenEdit \$8.5M + our early bird ends Friday!

Zymergen Announces \$400 Million in Series C Funding led by the SoftBank Vision Fund

The Ladder of Proof: How VCs see your startup

## How to win in the bioeconomy: A peek at Rob Carlson's playbook

Don't be left behind:  
**Subscribe to  
our weekly digest.**



The Global  
Synthetic Biology Summit  
**Oct. 1-3, San Francisco**


[REGISTER NOW](#)





**LIMITLESS GENES  
UNLIMITED DISCOVERY**

**T W I S T** BIO SCIENCE WE'RE READY FOR YOUR ORDER 



Which GeneArt™ technology is right for you?

**Use our guide**

**invitrogen**  
by Thermo Fisher Scientific



Sign up for  
BetaSpace Digest.

Our newsletter  
for the space settlement  
industry.

Editor's picks  

SOFTBANK VISION FUND



The Ladder of Proof:  
How VCs see your  
startup



How to win in the  
bioeconomy: A peek at  
Rob Carlson's  
playbook



Watch Panel "Bio is not  
another app: Investing  
in what's important" at  
SynBioBeta 2018



Winning iGEM team  
uses Opentrons to  
create a 3x faster  
chassis for genetic  
engineering



Top tips for building  
your biotech startup  
team

## Synthetic Biology Industry Strategy Reports

[Chemicals and Materials  
Biopharma and Healthcare  
Annual Investment Report](#)

Recent videos < >



SYNBIOBETA 2018



SynbiCITE webinar:  
Global trends and  
business opportunities  
in synbio



SynBioBeta Deep Dive  
– Amyris and Labcyte:  
Increasing strain  
construction efficiency  
and reducing reaction  
volumes



SynBioBetaLive! – Lab  
data to machine  
learning in 30 seconds  
with Riffyn

## Job opportunities

[Scientist, Strain Engineering at 64-x](#)

[Scientist, Microorganism  
Engineering at 64-x](#)

[Synthetic Biology Research  
Associate: LanzaTech](#)

[Head of Bioprocess: C16 Biosciences](#)

[Synthetic and Microbial Biologist:  
C16 Biosciences](#)

[More](#)

About





Industry Reports ▼

Working with us ▼

Resources ▼

Contact



SynBioBeta is the leading community of innovators, investors, engineers, and thinkers who share a passion for using synthetic biology to build a better, more sustainable universe. We're dedicated to telling the stories of the people and companies involved, building their networks, and helping them grow.



Join our weekly newsletter

SIGN UP

About ▼



Industry Reports ▼

Working with us ▼

Resources ▼

Contact

Copyright © SynBioBeta LLC 2018. All Rights Reserved.